Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

quest diagnostics inc. - DGX

DGX

Close Chg Chg %
190.83 -3.35 -1.76%

Closed Market

187.48

-3.35 (1.76%)

Volume: 762.52K

Last Updated:

May 8, 2026, 3:59 PM EDT

Trade Now

Company Overview: quest diagnostics inc. - DGX

DGX Key Data

Open

$192.00

 Day Range

186.23 - 192.20

52 Week Range

164.65 - 213.50

 Market Cap

$21.13B

Shares Outstanding

110.70M

 Public Float

110.12M

Beta

0.60

 Rev. Per Employee

N/A

P/E Ratio

21.05

 EPS

$9.17

Yield

170.82%

 Dividend

$0.86

EX-DIVIDEND DATE

Apr 6, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.05M

  

DGX Performance

1 Week
 
 -2.74%
 
1 Month
 
 -2.15%
 
3 Months
 
 -9.42%
 
1 Year
 
 5.89%
 
5 Years
 
 34.86%
 

DGX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 21
Full Ratings ➔

About quest diagnostics inc. - DGX

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information, and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to physicians, hospitals, patients, and consumers. The All Other segment consists of risk assessment services and healthcare information technology. The company was founded in 1967 and is headquartered in Secaucus, NJ.

DGX At a Glance

Quest Diagnostics, Inc.
500 Plaza Drive
Secaucus, New Jersey 07940
Phone 1-973-520-2700 Revenue 11.04B
Industry Services to the Health Industry Net Income 988.00M
Sector Health Services 2025 Sales Growth 11.781%
Fiscal Year-end 12 / 2026 Employees 57,000
View SEC Filings

DGX Valuation

P/E Current 21.051
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 19.847
Price to Sales Ratio 1.777
Price to Book Ratio 2.662
Price to Cash Flow Ratio 10.40
Enterprise Value to EBITDA 11.914
Enterprise Value to Sales 2.346
Total Debt to Enterprise Value 0.254

DGX Efficiency

Revenue/Employee 193,596.491
Income Per Employee 17,333.333
Receivables Turnover 7.837
Total Asset Turnover 0.682

DGX Liquidity

Current Ratio 1.044
Quick Ratio 0.961
Cash Ratio 0.184

DGX Profitability

Gross Margin 31.926
Operating Margin 14.527
Pretax Margin 11.944
Net Margin 8.953
Return on Assets 6.103
Return on Equity 14.167
Return on Total Capital 7.183
Return on Invested Capital 7.658

DGX Capital Structure

Total Debt to Total Equity 91.841
Total Debt to Total Capital 47.874
Total Debt to Total Assets 40.586
Long-Term Debt to Equity 79.554
Long-Term Debt to Total Capital 41.469
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Quest Diagnostics Inc. - DGX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
9.88B 9.25B 9.87B 11.04B
Sales Growth
-8.39% -6.38% +6.70% +11.78%
Cost of Goods Sold (COGS) incl D&A
6.54B 6.29B 6.73B 7.51B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
437.00M 439.00M 493.00M 570.00M
Depreciation
317.00M 331.00M 366.00M 416.00M
Amortization of Intangibles
120.00M 108.00M 127.00M 154.00M
COGS Growth
-1.68% -3.75% +6.91% +11.69%
Gross Income
3.35B 2.96B 3.15B 3.52B
Gross Income Growth
-19.15% -11.53% +6.25% +11.98%
Gross Profit Margin
+33.87% +32.00% +31.87% +31.93%
2022 2023 2024 2025 5-year trend
SG&A Expense
1.73B 1.61B 1.73B 1.92B
Research & Development
- - - -
-
Other SG&A
1.73B 1.61B 1.73B 1.92B
SGA Growth
+1.71% -6.67% +7.52% +10.92%
Other Operating Expense
- - - -
-
Unusual Expense
238.00M 87.00M 68.00M 49.00M
EBIT after Unusual Expense
1.38B 1.26B 1.35B 1.55B
Non Operating Income/Expense
(1.00M) 29.00M 54.00M 41.00M
Non-Operating Interest Income
10.00M 11.00M 25.00M 13.00M
Equity in Earnings of Affiliates
(55.00M) 20.00M 18.00M 19.00M
Interest Expense
148.00M 163.00M 226.00M 277.00M
Interest Expense Growth
-2.63% +10.14% +38.65% +22.57%
Gross Interest Expense
148.00M 163.00M 226.00M 277.00M
Interest Capitalized
- - - -
-
Pretax Income
1.24B 1.13B 1.18B 1.32B
Pretax Income Growth
-52.48% -8.50% +3.98% +12.17%
Pretax Margin
+12.50% +12.21% +11.90% +11.94%
Income Tax
264.00M 248.00M 273.00M 314.00M
Income Tax - Current - Domestic
262.00M 294.00M 256.00M 204.00M
Income Tax - Current - Foreign
1.00M 3.00M 4.00M 5.00M
Income Tax - Deferred - Domestic
2.00M (48.00M) 6.00M 76.00M
Income Tax - Deferred - Foreign
(1.00M) (1.00M) 7.00M 29.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
(55.00M) 20.00M 18.00M 19.00M
Other After Tax Income (Expense)
(4.00M) (4.00M) (5.00M) (4.00M)
Consolidated Net Income
1.01B 904.00M 916.00M 1.04B
Minority Interest Expense
69.00M 54.00M 50.00M 54.00M
Net Income
942.00M 850.00M 866.00M 988.00M
Net Income Growth
-52.62% -9.77% +1.88% +14.09%
Net Margin Growth
+9.53% +9.19% +8.77% +8.95%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
942.00M 850.00M 866.00M 988.00M
Preferred Dividends
- - - -
-
Net Income Available to Common
942.00M 850.00M 866.00M 988.00M
EPS (Basic)
8.1207 7.5893 7.8018 8.9009
EPS (Basic) Growth
-48.94% -6.54% +2.80% +14.09%
Basic Shares Outstanding
116.00M 112.00M 111.00M 111.00M
EPS (Diluted)
7.983 7.5221 7.6637 8.7434
EPS (Diluted) Growth
-48.60% -5.77% +1.88% +14.09%
Diluted Shares Outstanding
118.00M 113.00M 113.00M 113.00M
EBITDA
2.06B 1.79B 1.91B 2.17B
EBITDA Growth
-27.81% -13.06% +6.59% +13.89%
EBITDA Margin
+20.83% +19.35% +19.33% +19.69%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 225.733
Number of Ratings 21 Current Quarters Estimate 2.824
FY Report Date 06 / 2026 Current Year's Estimate 10.747
Last Quarter’s Earnings 2.50 Median PE on CY Estimate N/A
Year Ago Earnings 9.85 Next Fiscal Year Estimate 11.669
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 14 14 16 17
Mean Estimate 2.82 2.81 10.75 11.67
High Estimates 2.91 2.92 10.83 12.30
Low Estimate 2.75 2.74 10.55 11.33
Coefficient of Variance 1.52 1.66 0.61 1.90

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 8 7
OVERWEIGHT 2 2 2
HOLD 11 12 11
UNDERWEIGHT 0 0 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Quest Diagnostics Inc. - DGX

Date Name Shares Transaction Value
Nov 21, 2025 Mark E. Delaney SVP & Chief Commercial Officer 15,376 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $144.47 per share 2,221,370.72
Nov 21, 2025 Mark E. Delaney SVP & Chief Commercial Officer 15,476 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $143.33 per share 2,218,175.08
Nov 21, 2025 Mark E. Delaney SVP & Chief Commercial Officer 7,530 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $187.35 per share 1,410,745.50
Nov 21, 2025 Mark E. Delaney SVP & Chief Commercial Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 21, 2025 Mark E. Delaney SVP & Chief Commercial Officer 7,484 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 20, 2025 Denise M. Morrison Director 10,742 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Timothy M. Ring Director 29,507 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Gary M. Pfeiffer Director 30,669 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Timothy L. Main Director 26,297 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Robert B. Carter Director 2,685 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Vicky B. Gregg Director 18,138 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Tracey C. Doi Director 6,490 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Wright L. Lassiter Director 9,037 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Luis A. Diaz Director 4,054 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Quest Diagnostics Inc. in the News